Research containing WeChat
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned WeChat in 7 CB Insights research briefs, most recently on Mar 9, 2022.



Jul 23, 2020 report
Reopening: The Tech-Enabled Office In A Post-Covid World
Apr 2, 2020
Beauty Business Model Spotlight: Perfect DiaryWeChat Patents
WeChat has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/11/2015 | 10/4/2016 | Wireless networking, Mobile phones, Personal computers, Computer security, Global Positioning System | Grant |
Application Date | 5/11/2015 |
---|---|
Grant Date | 10/4/2016 |
Title | |
Related Topics | Wireless networking, Mobile phones, Personal computers, Computer security, Global Positioning System |
Status | Grant |
Latest WeChat News
May 13, 2022
(Yicai Global) May 13 -- Chinese biopharmaceutical firm HitGen has joined hands with US biotechnology company Arclight to develop new drugs for the treatment of central nervous system diseases. The pair will use Hitgen’s leading DNA-Encoded Compound Library and Targeted Protein Degradation technological platforms to detect and develop the innovative treatments for diseases including Alzheimer and Parkinson, the Chengdu-based company said on its official WeChat account today, citing the five-year strategic partnership agreement it signed with Arclight. The research and development of new medicines for central nervous system diseases is extremely difficult because of the non-druggability of relevant targets and the existence of the blood-brain barriers that make it hard for medicines to reach the lesions. No effective treatment has yet been found for many of such diseases. HitGen is a global leader in the sector of DEL technologies, said Steven Tregay, president and chief executive of Arclight. This partnership will assist the company’s TDP and non-TDP projects, as well as those related to new drugs in the screening of hit compounds, and boost the R&D of new drugs for central nervous system diseases. The news failed to boost HitGen’s shares. The stock [SHA: 688222] ended 1 percent down at CNY13.65 (USD2.01) today. Founded in 2012, HitGen has units in Cambridge, in the UK, and Houston, in the US. It has partnered with multiple international pharmaceutical and biotechnological companies. HitGen’s business revenue rose 27.7 percent to CNY310 million (USD45.6 million) last year from 2020, with net profit down 1 percent to CNY63.4 million (USD9.3 million). Its investment in core technological platforms and R&D of new drugs totaled CNY73.7 million, accounting for 23.7 percent of the overall business revenue. Arclight is the drug-detecting engine of Massachusetts-based Arclight Therapeutics. It focuses on the technology innovation and business incubation relevant to the R&D of treatments for neurodegenerative diseases. Editor: Futura Costaglione
WeChat Web Traffic
WeChat Rank
You May Also Like
Sandboxx is a military media company with media assets related to various military and veteran communities. The company's flagship app, Sandboxx provides secure and efficient communications for this community. Sandboxx's mission is to provide technology and solutions to simplify military and veteran lifestyle.

SoFi is an online personal finance company that helps people borrow, save, spend, invest, and protect their money all from a mobile device or desktop computer. The company provides the tools for people to do everything from one app on their phone.

Meta (NASDAQ: MVRS) is a social networking website that enables users to add friends and communicate with them via messages and to also update their personal profiles to notify their network of friends about themselves. The company's Facebook also allows its users to join networks organized by any variety of dimensions including by city, workplace, school, and region.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.